WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative dialysis products manufacturer serving the healthcare industry, today announced results for the third quarter and nine months ended September 30, 2003.

• Third quarter net income was $84,850, or $.01 per common share, compared with a net loss of ($182,852), or ($.02) per share for the third quarter of 2002.
  
  
• Third quarter net revenue increased to a record $3,939,000, a 37% increase over the same period in 2002.
  
  
• Gross profit margin increased to 18.1% in the third quarter compared with 14.4% in the third quarter last year.
  
  
• Net revenue for the first nine months of 2003 was $10,827,169; an increase of 37.2% over the same period in 2002.
  
  
• Dri-Sate® Dry Acid Concentrate sales increased 34% in the first nine months of 2003 as compared to the same period in 2002.
  
  

For the third quarter ended September 30, 2003, Rockwell Medical Technologies, Inc. reported net revenues increased 37% to a record $3,939,000 compared with net revenues of $2,882,853 for the same period in 2002. Net income for the third quarter of 2003 rose to a profit of $84,850 compared with a loss of ($182,852) in the same period in 2002. Net earnings per share for the third quarter of 2003 increased to $.01 compared with a loss of ($.02) in the same quarter of last year. Third quarter gross profit margins increased 3.7 percentage points to 18.1% compared with 14.4% in the third quarter of 2002.

Net revenues for the first nine months of 2003 increased 37.2% to $10,827,169 compared with net revenues of $7,890,777 for the first nine months of 2002. Gross profit margin increased 5.0 percentage points to 16.3% during the first nine months of 2003 compared to the same period in 2002. For the nine months ended September 30, 2003, year to date net loss was ($95,172) or ($.01) per share reflecting an $813,000 net income improvement or a $.11 per share improvement compared with the same period in 2002. The Company realized substantial growth in sales of its Dri-Sate® Dry Acid Concentrate product line with revenue up 34% compared to the first nine months of 2002.

Mr. Robert L. Chioini, Chairman, CEO, and President of Rockwell Medical Technologies, Inc. stated, “We are extremely pleased with these results. The third quarter was highlighted by record financial performance. This is a milestone achievement in Rockwell's development. As we entered 2003, we felt that our core business was positioned to achieve a profitable running rate by year-end. Increased sales volume coupled with enhanced operating and distribution efficiencies resulted in improved margins and operating results. The profitability of our core business should continue to improve as sales revenues increase. We also increased our expenditures during the third quarter for the development of our Dialysate Iron Therapy initiative and we are excited about the future potential that this innovative, proprietary product holds for Rockwell.”

Rockwell has licensed patents that give the Company exclusive, worldwide rights to manufacture, market and distribute dialysate solutions containing water soluble iron that can be administered to hemodialysis and peritoneal dialysis patients with renal failure. During Phase II clinical trials the iron compound ferric pyrophosphate, delivered to hemodialysis patients via dialysate, was well tolerated and proved to be effective at iron maintenance therapy without causing the serious side effects present with current intravenous (IV) iron products. The Company is required to obtain FDA approval to market its dialysate iron product. The Company estimates the domestic IV iron market to be approximately $270 million annually.

Rockwell will be holding a conference call to discuss its results on Thursday, November 6, 2003 at 11am EST. The call in number is 888-896-0862. The call will be available for replay on the Company's website, www.rockwellmed.com.

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Mixing System, RenalPure® Liquid Concentrate, SteriLyte® Liquid Bicarbonate, RenalPure® Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's business and operations, including the statements regarding the Company's ability to achieve a profitable level of operations and the potential of the Company's proprietary dialysate iron product, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors, failure to obtain FDA approval, and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc.announced today that it will hold a conference call on Thursday, November 6, 2003 at 11:00AM EST to discuss the results for the third quarter of 2003. Rob Chioini, Chairman and CEO, and Thomas Klema, CFO, will be hosting the call to review the release and answer questions from investors.

The call will be held on:

Thursday, November 6, 2003
Starting Time: 11:00AM Eastern Time
Dial in Number: 888-896-0862

When calling in please refer to the Rockwell Medical Technologies, 3rd Quarter Conference Call and provide the operator with your name and company affiliation.

Investors who prefer to participate using the internet may access the following link for Real Player:
http://orion.calleci.com/servlet/estreamgetevent?id=2974&folder=webstream

Or for Windows Media Player:
http://orion.calleci.com/servlet/estreamgetevent?id=2976&folder=webstream

International Investors may dial in directly on 973-935-8597

Investors who are unable to listen to the Rockwell earnings conference call will be able to access a replay via our web site at www.rockwellmed.com. There will be no telephone replay.

We appreciate your interest in Rockwell

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has extended the expiration date of its publicly traded warrants by twelve months to January 26, 2005

Rockwell warrants trade under the symbol RMTIW with an exercise price of $4.50 per Common Share. The warrants have a call feature and may be redeemed by the Company provided the bid price of the Common Shares has been at least $7.00 for 20 consecutive trading days ending on the third day prior to the date the notice of redemption is given.

Rockwell recently reported that its revenues for the six months ended June 30, 2003 were up 37.5% over the first six months of 2002. The Company is seeking FDA approval on a novel form of iron maintenance therapy using its dialysate concentrate to deliver iron to anemic dialysis patients. The current IV iron market is estimated to be $270,000,000. Rockwell anticipates competing in this market upon approval of its product.

The Company's stock price has increased five fold since the beginning of the year increasing from $.59 to over $3.00 in late trading yesterday.

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the patent approved Dri-Sate® Dry Acid Mixing System, Liquid Concentrate, SteriLyte® Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's business and operations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that its second quarter 2003 sales were $3,454,000, an increase of 35% over the second quarter of 2002. The Company's net loss was ($93,230) in the second quarter of 2003, which was a $285,000 improvement over the second quarter of 2002. Second quarter loss per share narrowed to ($.01), a $.04 per share improvement over the second quarter of 2002. The Company generated positive EBITDA in the second quarter of 2003.

Sales in the first half of 2003 increased 37.5% compared to the first half of 2002. Gross profit margin increased 5.7 percentage points to 15.2%. Net loss in the first half of 2003 was reduced to ($180,000), reflecting a $545,000 improvement compared to the first half of 2002. Loss per share for the six months ended June 30, 2003 improved to ($.02) as compared to ($.10) for the first six months of 2002.

The improvement in operating results was due to increased sales volume and improved operating efficiencies. The Company realized substantial growth from its Dri-Sate® Dry Acid Concentrate product line with sales revenue up 38% compared to the first half of 2002. Increased ancillary product sales, driven by increased sales of blood tubing, also contributed to the sales increase in 2003.

Mr. Robert L. Chioini, Chairman, CEO, and President of Rockwell Medical Technologies, Inc. stated, “We are pleased with the progress we have made in the first half of 2003. We have continued to experience a substantial increase in sales revenue, improvement in our gross profit margin and progress in the development and approval strategy of our dialysate iron product. Going forward, we have solid customer commitments and contracts that we expect will result in steady improvement in our sales growth during the second half of the year. We anticipate this continued development will enable Rockwell to achieve a profitable level of operations in its core concentrate business.”

Rockwell has licensed patents that give the Company exclusive, worldwide rights to manufacture, market and distribute dialysate solutions containing water soluble iron that can be administered to hemodialysis and peritoneal dialysis patients with renal failure. During Phase II clinical trials the iron compound ferric pyrophosphate, delivered to hemodialysis patients via dialysate, was well tolerated and proved to be effective at iron maintenance therapy without causing the serious side effects present with current intravenous (IV) iron products. The Company is required to obtain FDA approval to market its dialysate iron product. The Company estimates the IV iron market to be approximately $270 million.

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to work properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the patent-protected Dri-Sate® Dry Acid Mixing System, Liquid Concentrate, SteriLyte® Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's business and operations, including the statements regarding the Company's ability to achieve a profitable level of operations and the potential of the Company's proprietary dialysate iron product, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors, failure to obtain FDA approval, and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that it received notification from the U.S. Food and Drug Administration (FDA) that's its Dialysate Iron Concentrate has received product classification as a "combination product" for the approval process going forward. The allowed submission is a unique embedded classification (drug within a device).

The FDA's Center for Devices and Radiological Health (CDRH) will have lead responsibility for the combination product's premarket review and regulation. CDRH has advised that a premarket approval application (PMA) will be required. Complete information related to the drug component will be submitted to the Center for Drug Evaluation and Research (CDER) in a format similar to that required for a new drug application (NDA) as a separate section of the PMA. Clinical investigations of the combination product are already in progress under an investigational new drug (IND) application and will continue. CDER will retain lead responsibility for the clinical investigations and consult with CDRH as appropriate.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, “This determination of regulatory responsibility from the FDA is a significant milestone toward getting marketing approval in the U.S. for Dialysate Iron. This decision was consistent with our expectation and we are pleased that we can now proceed with the next steps in the FDA approval process. We believe Rockwell's Dialysate Iron has the potential to become the preferred dialysate in the provider market while at the same time to aggressively compete for the $270 million-plus U.S. iron maintenance therapy market.”

Rockwell's Dialysate Iron has two modes of action. One action of the product is to remove excess waste products and toxins from the blood of patients with renal failure, just like the Company's commercially available dialysate concentrates. Another action is to provide supplementary iron during the dialysis treatment as an alternative to maintenance oral or intravenous (IV) iron therapy to prevent the development of iron deficiency. The FDA determined that the dialysate (device) component's role represents the primary mode of action of the combination product.

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to work properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the patent-protected Dri-Sate® Dry Acid Mixing System, Liquid Concentrate, SteriLyte® Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's business and operations, including the statements regarding the potential of the Company's proprietary Dialysate Iron product, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors, failure to obtain FDA approval, and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that its first quarter 2003 sales were $3,435,000, an increase of 40.5% over the first quarter of 2002. First quarter loss per share narrowed to ($.01), a $.04 per share improvement over the first quarter of 2002. The Company generated a positive EBITDA in the first quarter.

First quarter sales growth of 40.5% was due to a combination of strong growth in the Company's core concentrate product lines and to the expansion of ancillary product sales. The Company realized substantial growth from its Dri-Sate® Dry Acid Concentrate product line with sales up 45% from a year ago. Ancillary product sales grew significantly, primarily because of increased sales of blood tubing.

The Company's net loss was ($86,793) in the first quarter of 2003, which was a $259,000 improvement over the first quarter of 2002. First quarter loss per share decreased to ($.01), as compared to a loss per share of ($.05) in 2001, with improved sales and operating margins driving the improvement in results.

Mr. Robert L. Chioini, Chairman, CEO, and President of Rockwell Medical Technologies, Inc. said, “We continue to increase our revenue base by aggressively marketing our core concentrate product line, primarily our patent-protected Dri-Sate® Dry Acid Concentrate Mixing System. The Dri-Sate® System enables us to gain new customers as well as expand on existing relationships with multi-site dialysis providers. As a result of our recently signed supply agreement with DaVita, coupled with continued sales penetration and improved operations, we believe Rockwell will achieve profitability in our core concentrate business.”

Mr. Chioini further stated, “We have been making sound progress in the development of our proprietary dialysate iron product. The Company anticipates initiating Phase III clinical trials for FDA approval of the product this year. Upon FDA approval, we believe this product will aggressively compete for the estimated $270 million iron maintenance therapy market.”

In 2002, the Company licensed the global rights to patents covering the inclusion of water-soluble iron in its dialysate products. During Phase II clinical trials, Ferric Pyrophosphate, delivered via dialysate, was well tolerated by patients and proved to be effective at iron maintenance therapy without causing the serious side effects present with current intravenous (IV) iron products. The Company is required to obtain FDA approval to market its dialysate iron product. The Company estimates the IV iron market to be approximately $270 million per year.

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to work properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the patent-protected Dri-Sate® Dry Acid Mixing System, Liquid Concentrate, SteriLyte® Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's business and operations, including the statements regarding the Company's ability to achieve a profitable level of operations in 2003 and the potential of the Company's proprietary dialysate iron product, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors, failure to obtain FDA approval, and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has renewed its line of credit with GE Healthcare Financial Services. The two year loan agreement has a credit limit of $2,500,000.

Under the terms of the loan agreement, the credit facility can increase up to $2,500,000 based on the growth in the Company's accounts receivable. The loan facility is secured by the Company's accounts receivable and other assets. The Company is obligated to pay interest at the rate of two percentage points over the prime rate. The loan facility expires March 29, 2005 and is renewable on an annual basis, thereafter, at the option of both parties.

Mr. Thomas E. Klema, Vice President and Chief Financial Officer stated “We are pleased to extend our relationship with GE Healthcare Financial Services. The increased financing availability should provide Rockwell with additional working capital resources to support the expansion of business operations consistent with the Company's business strategy.”

On March 13, 2003, Rockwell announced that it has signed a significant supply contract with DaVita, Inc., the second largest dialysis provider in the United States, to supply an additional 100 DaVita clinics with Rockwell products including Rockwell's patented Dri-Sate® Dry Acid Mixing System and concentrate product line. The Company also reported on February 25, 2003 that its sales revenue increased 54% in the fourth quarter of 2002 as compared to the fourth quarter of 2001.

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the patent approved Dri-Sate® Dry Acid Mixing System, Liquid Concentrate, SteriLyte® Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's business and operations constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that it has signed a supply contract with DaVita Inc. (NYSE: DVA). Rockwell estimates that the supply contract could generate approximately $3.5 million in annualized sales revenue. Rockwell anticipates that the revenue from the supply contract will result in the Company's operations becoming profitable.

DaVita Inc., headquartered in Torrance, CA, is the largest independent provider of dialysis services in the United States for patients suffering from chronic kidney failure. The company owns and operates kidney dialysis centers and home peritoneal dialysis programs domestically in 33 states, as well as Washington, D.C. DaVita currently operates 515 outpatient dialysis facilities serving over 45,000 patients, including 3,300 patients in 30 centers under management. The company also provides acute hemodialysis services to inpatients at approximately 280 hospitals.

Under the supply contract, DaVita may purchase Dri-Sate® Dry Acid Concentrate and bicarbonate powder from Rockwell. DaVita may also purchase liquid concentrate from Rockwell. The supply contract has a term of two years but may be extended annually upon mutual agreement of Rockwell and DaVita.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell said, “We are pleased to expand our business relationship with DaVita. We believe the business generated from this supply contract will enable Rockwell to achieve a profitable level of operations. DaVita is a well-respected dialysis provider and this supply contract is a significant endorsement for Rockwell and its ability to provide innovative products, exceptional customer service and timely delivery to the dialysis community. Rockwell's Dri-Sate® Dry Acid Mixing System is an effective way for dialysis providers to lower their cost per treatment and better utilize their clinic storage space.”

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the patent approved Dri-Sate® Dry Acid Mixing System, Liquid Concentrate, SteriLyte® Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's business and operations constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that its fourth quarter 2002 sales were $3,605,000, an increase of 54.4% over the fourth quarter of 2001. Fourth quarter revenue was the highest in the Company's history. Fourth quarter loss per share was ($.01) on a loss of ($73,000), which was an improvement of $405,000 over the fourth quarter of 2001. The Company achieved positive EBITDA results in the fourth quarter.

Sales for 2002 were $11,495,700, an increase of 27.5% over 2001. The Company realized substantial growth from its Dri-Sate® Dry Acid Concentrate product line, an overall increase in its dialysis concentrate product sales and the expansion of its ancillary product line sales, including blood tubing and fistula needles. The Company's operating loss was ($980,711) in 2002 as compared to ($1,579,103) in 2001, a 37.9% reduction. Loss per share for 2002 was ($.12) as compared to a loss per share of ($.26) in 2001. An increase in the number of outstanding shares accounted for $.04 of the improvement in loss per share

Mr. Robert L. Chioini, Chairman, CEO, and President of Rockwell Medical Technologies, Inc. said, “Rockwell's strong fourth quarter was the result of the Company's success in business and operational development during the last year. Dialysis providers continue to be attracted to the economic benefits of our Dri-Sate® Dry Acid Concentrate product line and it has resulted in substantial volume increases across all of our product lines. Ancillary product sales, with the addition of blood tubing, more than doubled in 2002. In addition, we expanded our production capacity and geographic reach during 2002 and those efforts led to substantial sales growth and improved operational results.”

Mr. Chioini also stated, “Our results improved dramatically in the fourth quarter with the Company achieving EBITDA positive results and a substantial reduction in its operating loss. Gross profit margins increased, driven by operational improvements from more efficient manufacturing equipment, enhanced distribution efficiencies and overall sales volume increases in our business. We believe that Rockwell can achieve a profitable level of operations from its dialysis concentrate and supply business in 2003. In addition, we believe the Company's proprietary dialysate iron product holds high potential to aggressively compete for the substantial iron maintenance therapy market once approved by the FDA.”

In January of 2002, the Company reported that it had licensed the global rights to patents covering the inclusion of water soluble iron in its dialysate products. During Phase II clinical trials, Ferric Pyrophosphate, delivered via dialysate, was well tolerated by patients and proved to be effective at iron maintenance therapy without causing the serious side effects present with current intravenous (IV) iron products. The Company is required to obtain FDA approval to market its dialysate iron product. The Company estimates the domestic IV iron market to be approximately $270 million.

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items including blood tubing. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

Certain statements in this press release, including the statements regarding the Company's ability to achieve a profitable level of operations in 2003 and the potential of the Company's proprietary dialysate iron product, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors, failure to obtain FDA approval, and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis products manufacturer in the healthcare industry, announced today that it plans to report its fourth quarter earnings on Tuesday, February 25, 2003. The Company anticipates reporting strong sales growth for the fourth quarter of 2002.

Rockwell Medical Technologies, Inc. expects to report sales of at least $3.5 million in the fourth quarter of 2002, which is an increase of over 50% above reported revenue in the fourth quarter of 2001. The Company also generated positive EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization) in the fourth quarter consistent with the Company's previously stated expectations.

Thomas E. Klema, Vice President and Chief Financial Officer stated, “The Company felt it was important to provide interim guidance to investors on anticipated results for the fourth quarter. Rockwell's business has made substantial improvement in the fourth quarter by generating increased sales, leading to both reduced operating losses and cash requirements to fund business operations.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the patent approved Dri-Sate® Dry Acid Mixing System, Liquid Concentrate, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release including estimates of additional sales revenue expected to be generated under the new supply agreement constitute"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.


(Return to News Index)